No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, double-blind, placebo- controlled clinical trials

Annals of Neurology

Volumn 47, Issue 2, 2000, Pages 238-241

  Roon, K I ^a   Olesen, J ^c   Diener, H C ^d   Ellis, P ^e   Hettiarachchi, J ^e   Poole, P H ^e   Christianssen, I ^c   Kleinermans, D ^f   Kok, J G ^b   Ferrari, M D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Location Alkmaar   (Netherlands)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^f ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; EXTRAVASATION; FEMALE; HUMAN; MALE; MIGRAINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NEUROGENIC INFLAMMATION; PLACEBOS; PYRROLIDINES; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT FAILURE;

EID: 0033951752     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200002)47:2<238::AID-ANA15>3.0.CO;2-L     Document Type: Article

References (16)

1. Maassen VanDenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30
2. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-311
3. 1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation. Br J Pharmacol 1995; 116:2385-2390
4. Lee WS, Moskowitz MA. Conformationally restricted sumatriptan analogues CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res 1993;626:303-305
5. Ellis P, Jenkins VC, Kleinermans D, et al. The safety, tolerability and pharmacokinetics of CP-122,288 in healthy volunteers. Cephalalgia 1997;17:409-410
6. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988; 8(Suppl 7):1-96
7. 1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996;46:522-526
8. Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled dose-ranging study. Arch Neurol 1996;53:1132-1137
9. May A, Gijsman HJ, Wallnöfer A, et al. Endothelin antagonist bosentan blocks neurogenic inflammation but is not effective in aborting migraine attacks. Pain 1996;67:375-378
10. 1 receptor antagonist in the acute treatment of migraine. Cephalalgia 1998;18:392 (Abstract)
11. 1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalalgia 1998;38:380 (Abstract)
12. Goldstein DJ, Wang O, Saper JR, et al. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997;17:785-790
13. Diener HC (for the RPR 100893 Migraine Study Group). Substance-P antagonist RPR 100893/201 is not effective in human migraine attacks. In: Olesen J, Tfelt-Hansen P, eds. Proceedings of the VIth International Headache Seminar. New York: Lippincott-Raven, 1996
14. Data J, Britch K, Westergaard N. A double-blind study of ganaxolone in the acute treatment of migraine headache with or without an aura in premenopausal females. Headache 1998;38: 380 (Abstract)
15. Nissilä M, Parkkola R, Sonninen P, et al. Intracerebral arteries and gadolinium enhancement in migraine without aura. Cephalalgia 1996;16:363 (Abstract)
16. May A, Shepheard SL, Knorr M, et al. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain 1998;121:1231-1237